Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Downregulation of the S1P Transporter Spinster Homology Protein 2 (Spns2) Exerts an Anti-Fibrotic and Anti-Inflammatory Effect in Human Renal Proximal Tubular Epithelial Cells.

Blanchard O, Stepanovska B, Starck M, Erhardt M, Römer I, Meyer Zu Heringdorf D, Pfeilschifter J, Zangemeister-Wittke U, Huwiler A.

Int J Mol Sci. 2018 May 17;19(5). pii: E1498. doi: 10.3390/ijms19051498.

2.

The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives.

Huwiler A, Zangemeister-Wittke U.

Pharmacol Ther. 2018 May;185:34-49. doi: 10.1016/j.pharmthera.2017.11.001. Epub 2017 Nov 8. Review.

PMID:
29127024
3.

Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.

Graumann R, Di Capua GA, Oyarzún JE, Vásquez MA, Liao C, Brañes JA, Roa I, Casanello P, Corvalán AH, Owen GI, Delgado I, Zangemeister-Wittke U, Ziegler A.

PLoS One. 2017 May 4;12(5):e0177244. doi: 10.1371/journal.pone.0177244. eCollection 2017.

4.

Upregulation of the S1P3 receptor in metastatic breast cancer cells increases migration and invasion by induction of PGE2 and EP2/EP4 activation.

Filipenko I, Schwalm S, Reali L, Pfeilschifter J, Fabbro D, Huwiler A, Zangemeister-Wittke U.

Biochim Biophys Acta. 2016 Nov;1861(11):1840-1851. doi: 10.1016/j.bbalip.2016.09.005. Epub 2016 Sep 9.

PMID:
27616330
5.

Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins.

Merten H, Brandl F, Plückthun A, Zangemeister-Wittke U.

Bioconjug Chem. 2015 Nov 18;26(11):2176-85. doi: 10.1021/acs.bioconjchem.5b00260. Epub 2015 Jul 8.

PMID:
26086208
6.

Sphingosine kinase 2 deficiency increases proliferation and migration of renal mouse mesangial cells and fibroblasts.

Schwalm S, Timcheva TM, Filipenko I, Ebadi M, Hofmann LP, Zangemeister-Wittke U, Pfeilschifter J, Huwiler A.

Biol Chem. 2015 Jun;396(6-7):813-25. doi: 10.1515/hsz-2014-0289.

7.

Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting.

Stefan N, Zimmermann M, Simon M, Zangemeister-Wittke U, Plückthun A.

Bioconjug Chem. 2014 Dec 17;25(12):2144-56. doi: 10.1021/bc500468s. Epub 2014 Nov 14.

PMID:
25350699
8.

The ceramide kinase inhibitor NVP-231 inhibits breast and lung cancer cell proliferation by inducing M phase arrest and subsequent cell death.

Pastukhov O, Schwalm S, Zangemeister-Wittke U, Fabbro D, Bornancin F, Japtok L, Kleuser B, Pfeilschifter J, Huwiler A.

Br J Pharmacol. 2014 Dec;171(24):5829-44. doi: 10.1111/bph.12886.

9.

Ceramide kinase contributes to proliferation but not to prostaglandin E2 formation in renal mesangial cells and fibroblasts.

Pastukhov O, Schwalm S, Römer I, Zangemeister-Wittke U, Pfeilschifter J, Huwiler A.

Cell Physiol Biochem. 2014;34(1):119-33. doi: 10.1159/000362989. Epub 2014 Jun 16.

10.

Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation.

Simon M, Stefan N, Borsig L, Plückthun A, Zangemeister-Wittke U.

Mol Cancer Ther. 2014 Feb;13(2):375-85. doi: 10.1158/1535-7163.MCT-13-0523. Epub 2013 Nov 1.

11.

Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension.

Simon M, Frey R, Zangemeister-Wittke U, Plückthun A.

Bioconjug Chem. 2013 Nov 20;24(11):1955-66. doi: 10.1021/bc4004102. Epub 2013 Nov 11.

PMID:
24168270
12.

AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells.

Rabi T, Huwiler A, Zangemeister-Wittke U.

Mol Carcinog. 2014 Jul;53(7):578-88. doi: 10.1002/mc.22012. Epub 2013 Mar 8.

PMID:
23475563
13.

Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy.

Simon M, Stefan N, Plückthun A, Zangemeister-Wittke U.

Expert Opin Drug Deliv. 2013 Apr;10(4):451-68. doi: 10.1517/17425247.2013.759938. Epub 2013 Jan 14. Review.

PMID:
23316711
14.

Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer.

Wojtalla A, Fischer B, Kotelevets N, Mauri FA, Sobek J, Rehrauer H, Wotzkow C, Tschan MP, Seckl MJ, Zangemeister-Wittke U, Arcaro A.

Clin Cancer Res. 2013 Jan 1;19(1):96-105. doi: 10.1158/1078-0432.CCR-12-1138. Epub 2012 Nov 21.

15.

Targeting sphingosine kinase 1 in carcinoma cells decreases proliferation and survival by compromising PKC activity and cytokinesis.

Kotelevets N, Fabbro D, Huwiler A, Zangemeister-Wittke U.

PLoS One. 2012;7(6):e39209. doi: 10.1371/journal.pone.0039209. Epub 2012 Jun 25. Erratum in: PLoS One. 2013;8(10). doi:10.1371/annotation/cf556c9c-8c18-4d54-b34f-7a2e0c9339e3.

16.

High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes.

Heine M, Freund B, Nielsen P, Jung C, Reimer R, Hohenberg H, Zangemeister-Wittke U, Wester HJ, Lüers GH, Schumacher U.

PLoS One. 2012;7(5):e36258. doi: 10.1371/journal.pone.0036258. Epub 2012 May 8.

17.

Facile double-functionalization of designed ankyrin repeat proteins using click and thiol chemistries.

Simon M, Zangemeister-Wittke U, Plückthun A.

Bioconjug Chem. 2012 Feb 15;23(2):279-86. doi: 10.1021/bc200591x. Epub 2012 Jan 20.

PMID:
22188139
18.

DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency.

Stefan N, Martin-Killias P, Wyss-Stoeckle S, Honegger A, Zangemeister-Wittke U, Plückthun A.

J Mol Biol. 2011 Nov 4;413(4):826-43. doi: 10.1016/j.jmb.2011.09.016. Epub 2011 Sep 21.

PMID:
21963989
19.

A prokaryotic S1P lyase degrades extracellular S1P in vitro and in vivo: implication for treating hyperproliferative disorders.

Huwiler A, Bourquin F, Kotelevets N, Pastukhov O, Capitani G, Grütter MG, Zangemeister-Wittke U.

PLoS One. 2011;6(8):e22436. doi: 10.1371/journal.pone.0022436. Epub 2011 Aug 1.

20.

Neuronal differentiation by indomethacin and IBMX inhibits proliferation of small cell lung cancer cells in vitro.

Lange A, Gustke H, Glassmeier G, Heine M, Zangemeister-Wittke U, Schwarz JR, Schumacher U, Lange T.

Lung Cancer. 2011 Nov;74(2):178-87. doi: 10.1016/j.lungcan.2011.03.017. Epub 2011 Apr 21.

PMID:
21511354
21.

A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.

Martin-Killias P, Stefan N, Rothschild S, Plückthun A, Zangemeister-Wittke U.

Clin Cancer Res. 2011 Jan 1;17(1):100-10. doi: 10.1158/1078-0432.CCR-10-1303. Epub 2010 Nov 12. Erratum in: Clin Cancer Res. 2011 Jun 1;17(11):3850. Patricia, Martin-Killias [corrected to Martin-Killias, Patricia].

22.

Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage.

Huwiler A, Kotelevets N, Xin C, Pastukhov O, Pfeilschifter J, Zangemeister-Wittke U.

Br J Pharmacol. 2011 Jan;162(2):532-43. doi: 10.1111/j.1476-5381.2010.01053.x.

23.

EpCAM-targeted delivery of nanocomplexed siRNA to tumor cells with designed ankyrin repeat proteins.

Winkler J, Martin-Killias P, Plückthun A, Zangemeister-Wittke U.

Mol Cancer Ther. 2009 Sep;8(9):2674-83. doi: 10.1158/1535-7163.MCT-09-0402. Epub 2009 Sep 1.

24.

Increased numbers of spontaneous SCLC metastasis in absence of NK cells after subcutaneous inoculation of different SCLC cell lines into pfp/rag2 double knock out mice.

Sodeur S, Ullrich S, Gustke H, Zangemeister-Wittke U, Schumacher U.

Cancer Lett. 2009 Sep 18;282(2):146-51. doi: 10.1016/j.canlet.2009.03.005. Epub 2009 Apr 5.

PMID:
19349111
25.
26.

AKT/mTOR pathway activation and BCL-2 family proteins modulate the sensitivity of human small cell lung cancer cells to RAD001.

Marinov M, Ziogas A, Pardo OE, Tan LT, Dhillon T, Mauri FA, Lane HA, Lemoine NR, Zangemeister-Wittke U, Seckl MJ, Arcaro A.

Clin Cancer Res. 2009 Feb 15;15(4):1277-87. doi: 10.1158/1078-0432.CCR-08-2166.

27.

TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.

Belyanskaya LL, Ziogas A, Hopkins-Donaldson S, Kurtz S, Simon HU, Stahel R, Zangemeister-Wittke U.

Lung Cancer. 2008 Jun;60(3):355-65. Epub 2008 Feb 21.

PMID:
18093694
28.

Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system.

Hussain S, Plückthun A, Allen TM, Zangemeister-Wittke U.

Mol Cancer Ther. 2007 Nov;6(11):3019-27.

29.

Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression.

Giorgini S, Trisciuoglio D, Gabellini C, Desideri M, Castellini L, Colarossi C, Zangemeister-Wittke U, Zupi G, Del Bufalo D.

Mol Cancer Res. 2007 Aug;5(8):761-71.

30.

Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy.

Huwiler A, Zangemeister-Wittke U.

Crit Rev Oncol Hematol. 2007 Aug;63(2):150-9. Epub 2007 Jun 7. Review.

PMID:
17560117
31.

Antisense targeting of Mcl-1 has therapeutic potential in gastric cancer.

Zangemeister-Wittke U, Huwiler A.

Cancer Biol Ther. 2006 Oct;5(10):1355-6. Epub 2006 Oct 14. No abstract available.

PMID:
17172809
32.

Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL.

Hussain S, Plückthun A, Allen TM, Zangemeister-Wittke U.

Mol Cancer Ther. 2006 Dec;5(12):3170-80.

33.

Antisense-mediated melanoma inhibitor of apoptosis protein downregulation sensitizes G361 melanoma cells to cisplatin.

Mousavi-Shafaei P, Ziaee AA, Azizi E, Zangemeister-Wittke U.

Anticancer Drugs. 2006 Oct;17(9):1031-9.

PMID:
17001176
34.

PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting.

Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Plückthun A.

J Biol Chem. 2006 Nov 17;281(46):35186-201. Epub 2006 Sep 8.

35.

p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma.

Hopkins-Donaldson S, Belyanskaya LL, Simões-Wüst AP, Sigrist B, Kurtz S, Zangemeister-Wittke U, Stahel R.

Neoplasia. 2006 Jul;8(7):551-9.

36.

Antisense molecules for targeted cancer therapy.

Wacheck V, Zangemeister-Wittke U.

Crit Rev Oncol Hematol. 2006 Jul;59(1):65-73. Epub 2006 Jun 5. Review.

PMID:
16750913
37.
38.

Antibodies for targeted cancer therapy -- technical aspects and clinical perspectives.

Zangemeister-Wittke U.

Pathobiology. 2005;72(6):279-86. Review.

PMID:
16582579
39.
40.

Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation.

Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, Simões-Wüst AP, Yousefi S, Simon HU, Stahel R, Zangemeister-Wittke U.

Int J Cancer. 2005 Dec 10;117(5):755-63.

41.

Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function.

Del Bufalo D, Rizzo A, Trisciuoglio D, Cardinali G, Torrisi MR, Zangemeister-Wittke U, Zupi G, Biroccio A.

Cell Death Differ. 2005 Nov;12(11):1429-38.

42.

Apoptosis regulation and drug resistance in malignant pleural mesothelioma.

Zangemeister-Wittke U, Hopkins-Donaldson S.

Lung Cancer. 2005 Jul;49 Suppl 1:S105-8. No abstract available.

PMID:
15888351
43.

DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells.

Simões-Wüst AP, Sigrist B, Belyanskaya L, Hopkins Donaldson S, Stahel RA, Zangemeister-Wittke U.

J Neurooncol. 2005 Mar;72(1):29-34.

PMID:
15803372
44.

A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.

Simões-Wüst AP, Hopkins-Donaldson S, Sigrist B, Belyanskaya L, Stahel RA, Zangemeister-Wittke U.

Oligonucleotides. 2004;14(3):199-209.

PMID:
15625915
45.

Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.

Milella M, Trisciuoglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A, Cognetti F, Zangemeister-Wittke U, Del Bufalo D, Zupi G.

Clin Cancer Res. 2004 Nov 15;10(22):7747-56.

46.

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma.

Aguirre D, Boya P, Bellet D, Faivre S, Troalen F, Benard J, Saulnier P, Hopkins-Donaldson S, Zangemeister-Wittke U, Kroemer G, Raymond E.

Apoptosis. 2004 Nov;9(6):797-805.

PMID:
15505422
47.

An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy.

Zangemeister-Wittke U, Simon HU.

Cell Cycle. 2004 Sep;3(9):1121-3. Epub 2004 Sep 15. Review.

PMID:
15326382
48.

Inflammation-associated cell cycle-independent block of apoptosis by survivin in terminally differentiated neutrophils.

Altznauer F, Martinelli S, Yousefi S, Thürig C, Schmid I, Conway EM, Schöni MH, Vogt P, Mueller C, Fey MF, Zangemeister-Wittke U, Simon HU.

J Exp Med. 2004 May 17;199(10):1343-54.

49.

An antisense oligonucleotide to cIAP-1 sensitizes prostate cancer cells to fas and TNFalpha mediated apoptosis.

McEleny K, Coffey R, Morrissey C, Williamson K, Zangemeister-Wittke U, Fitzpatrick JM, Watson RW.

Prostate. 2004 Jun 1;59(4):419-25.

PMID:
15065090
50.

Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling.

Zangemeister-Wittke U.

Ann N Y Acad Sci. 2003 Dec;1002:90-4.

PMID:
14751826

Supplemental Content

Loading ...
Support Center